Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Completes Synteni Acquisition, Begins to Integrate Product Lines

Premium

PALO ALTO, Calif.--Incyte Pharmaceuticals has completed its acquisition of the gene expression microarray company Synteni that was announced in December. The transaction involves Incyte's issuing shares of its common stock in exchange for all of Synteni's outstanding equity.

"The integration of Synteni's proven microarray technology and Incyte's genomic information is well underway," commented Randy Scott, Incyte's president and chief scientific officer. "We have already identified and initiated development of a series of new microarray products for launch beginning this year, including two microarrays with applications in pharmacology and toxicology and a panel of microarrays comprising Incyte's entire set of human genes. Combined with Incyte's efforts to identify every human gene, this program should enable us to provide our pharmaceutical partners with the ability to scan virtually every gene in the human genome across any biological sample by the year 2000."

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.